TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 15155305

Group type: EXPERIMENTAL
Intervention: DBRCT.af computer search strategy
Number of subjects: 0

Group type: COMPARATOR
Intervention: Optimally Sensitive Search Strategy
Number of subjects: 0

Group type: COMPARATOR
Intervention: RCT.pt standard MEDLINE strategy
Number of subjects: 0

Group type: COMPARATOR
Intervention: DBRCT.af computer algorithm
Number of subjects: 0
Study: 11847826

Group type: EXPERIMENTAL
Intervention: Manual breast pump (MP)
Number of subjects: 60

Group type: COMPARATOR
Intervention: Mini-electric breast pump (MEP)
Number of subjects: 60
Study: 9492093

Group type: EXPERIMENTAL
Intervention: Free fraction of L-tryptophan in plasma
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: L-tryptophan and serotonin synthesis
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Free fraction of plasma L-tryptophan
Number of subjects: 0
Study: 8830646

Group type: EXPERIMENTAL
Intervention: Diltiazem-R (100mg)
Number of subjects: 7

Group type: EXPERIMENTAL
Intervention: Atenolol (50mg)
Number of subjects: 7

Group type: COMPARATOR
Intervention: Control (no treatment)
Number of subjects: 7
Study: 3266541

Group type: EXPERIMENTAL
Intervention: Sodium metabisulfite solutions (0.5, 1, 10, 25, 50 mg, 100 mg, 200 mg)
Number of subjects: 44

Group type: COMPARATOR
Intervention: Lactose-placebo
Number of subjects: 44
Study: 29682865

Group type: EXPERIMENTAL
Intervention: Forced-air warming (n=64)
Number of subjects: 127

Group type: COMPARATOR
Intervention: Passive insulation (n=63)
Number of subjects: 127
Study: 27465318

Group type: EXPERIMENTAL
Intervention: Therapeutic recreation program (TR-EF) delivered through electronically based games during 200 1-hour sessions (5/week) for 40 weeks
Number of subjects: 37

Group type: COMPARATOR
Intervention: Wait-list control group
Number of subjects: 37
Study: 26092062

Group type: EXPERIMENTAL
Intervention: Weekly teriparatide
Number of subjects: 542
Study: 24019415

Group type: EXPERIMENTAL
Intervention: Moderate to severe cerebral palsy (Mod/Sev CP)
Number of subjects: 115

Group type: COMPARATOR
Intervention: No cerebral palsy (No CP)
Number of subjects: 115

Group type: EXPERIMENTAL
Intervention: Gastrostomy feeds
Number of subjects: 115
Study: 22132861

Group type: EXPERIMENTAL
Intervention: Implementation strategy (training session, information, opinion leader, reminders, audit, and feedback)
Number of subjects: 296

Group type: COMPARATOR
Intervention: Usual diffusion (control group)
Number of subjects: 296

Group type: EXPERIMENTAL
Intervention: Implementation strategy
Number of subjects: 296
Study: 19487264

Group type: EXPERIMENTAL
Intervention: Alendronate 70 mg once weekly
Number of subjects: 173

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 173
Study: 17029118

Group type: EXPERIMENTAL
Intervention: Laryngeal Mask Airway (LMA)
Number of subjects: 96

Group type: EXPERIMENTAL
Intervention: Cuffed Oropharyngeal Airway (COPA)
Number of subjects: 96

Group type: COMPARATOR
Intervention: Endotracheal Tube (ETT)
Number of subjects: 96
Study: 12617709

Group type: EXPERIMENTAL
Intervention: Age 50 to 59 years
Number of subjects: 2041

Group type: EXPERIMENTAL
Intervention: Age 80 years and older
Number of subjects: 2041

Group type: EXPERIMENTAL
Intervention: Participants 70 years and older
Number of subjects: 2041
Study: 11025425

Group type: EXPERIMENTAL
Intervention: Neoadjuvant hormonal therapy (NHT) prior to radical prostatectomy
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Neoadjuvant hormonal therapy (NHT) prior to radiation therapy
Number of subjects: 0

Group type: COMPARATOR
Intervention: Radiation only
Number of subjects: 0

Group type: COMPARATOR
Intervention: Surgery only
Number of subjects: 0
Study: 9105988

Group type: EXPERIMENTAL
Intervention: Inhaled nitric oxide (NO) at 40 ppm
Number of subjects: 6

Group type: COMPARATOR
Intervention: Control condition (ventilated with 70% oxygen and 30% nitrogen)
Number of subjects: 6
Study: 8444251

Group type: EXPERIMENTAL
Intervention: Fortifier A (bovine proteins, peptides, and amino acids)
Number of subjects: 24

Group type: COMPARATOR
Intervention: Fortifier B (freeze-dried skimmed human milk and minerals)
Number of subjects: 24
Study: 3770017

Group type: EXPERIMENTAL
Intervention: Propranolol
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Sotalol
Number of subjects: 30

Group type: COMPARATOR
Intervention: Propranolol and diuretic
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Sotalol and diuretic
Number of subjects: 30
Study: 30957240

Group type: EXPERIMENTAL
Intervention: Intervention group (INT)
Number of subjects: 746

Group type: COMPARATOR
Intervention: Adherent patients (ADH)
Number of subjects: 746
Study: 29531173

Group type: EXPERIMENTAL
Intervention: Intensive group (always alone)
Number of subjects: 4082

Group type: EXPERIMENTAL
Intervention: Intensive group (never alone)
Number of subjects: 4082

Group type: EXPERIMENTAL
Intervention: Intensive group (alone for rest)
Number of subjects: 4082

Group type: EXPERIMENTAL
Intervention: Intensive group (alone for BP measurement)
Number of subjects: 4082

Group type: COMPARATOR
Intervention: Standard group (always alone)
Number of subjects: 4082

Group type: COMPARATOR
Intervention: Standard group (never alone)
Number of subjects: 4082

Group type: COMPARATOR
Intervention: Standard group (alone for rest)
Number of subjects: 4082

Group type: COMPARATOR
Intervention: Standard group (alone for BP measurement)
Number of subjects: 4082
Study: 26914585

Group type: EXPERIMENTAL
Intervention: Influenza vaccine (H1N1 strain)
Number of subjects: 133

Group type: EXPERIMENTAL
Intervention: Influenza vaccine (H3N2 strain)
Number of subjects: 133

Group type: EXPERIMENTAL
Intervention: Influenza vaccine (B strain)
Number of subjects: 133
Study: 23733907

Group type: EXPERIMENTAL
Intervention: Cytology only at baseline
Number of subjects: 1100

Group type: EXPERIMENTAL
Intervention: Repeat cytology after negative baseline cytology
Number of subjects: 1100

Group type: EXPERIMENTAL
Intervention: Baseline HPV16/18 genotyping
Number of subjects: 1100

Group type: EXPERIMENTAL
Intervention: Both HPV16/18 genotyping at baseline and repeat cytology testing
Number of subjects: 1100
Study: 22640372

Group type: EXPERIMENTAL
Intervention: Osteo-cise intervention (multi-modal exercise program with high velocity progressive resistance training, moderate impact weight-bearing exercise, and high challenging balance exercises performed three times weekly)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Self-management control group
Number of subjects: 0
Study: 20119672

Group type: EXPERIMENTAL
Intervention: Intraoperative periarticular multimodal drug injections (PMDI)
Number of subjects: 55

Group type: COMPARATOR
Intervention: No-PMDI (control group)
Number of subjects: 55
Study: 17653518

Group type: EXPERIMENTAL
Intervention: TTE sizing as the sole tool for selecting device size in group 2 (10 patients)
Number of subjects: 40

Group type: COMPARATOR
Intervention: Balloon sizing and TTE sizing in group 1 (30 patients)
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: TTE sizing
Number of subjects: 40
Study: 16039414

Group type: EXPERIMENTAL
Intervention: Cimicifuga racemosa extract (Cr 99)
Number of subjects: 122

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 122
Study: 12095018

Group type: EXPERIMENTAL
Intervention: Tramadol 50 mg
Number of subjects: 47

Group type: COMPARATOR
Intervention: Meperidine 50 mg
Number of subjects: 47

Group type: COMPARATOR
Intervention: Meperidine (rescue medication)
Number of subjects: 47
Study: 9474073

Group type: EXPERIMENTAL
Intervention: Glucocorticoids
Number of subjects: 0

Group type: COMPARATOR
Intervention: Randomly selected controls
Number of subjects: 0
Study: 8919987

Group type: EXPERIMENTAL
Intervention: morphine 0.50 mg/ml + ketorolac 1.50 mg/ml (Group 2)
Number of subjects: 180

Group type: EXPERIMENTAL
Intervention: morphine 0.75 mg/ml + ketorolac 0.75 mg/ml (Group 1)
Number of subjects: 180

Group type: EXPERIMENTAL
Intervention: morphine 0.25 mg/ml + ketorolac 1.50 mg/ml (Group 3)
Number of subjects: 180
Study: 2136826

Group type: EXPERIMENTAL
Intervention: Ipratropium bromide (40 micrograms, 200 micrograms, and 800 micrograms)
Number of subjects: 9

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 9

Group type: EXPERIMENTAL
Intervention: Ipratropium bromide
Number of subjects: 9
Study: 400713

Group type: EXPERIMENTAL
Intervention: Intravenous insulin (iv)
Number of subjects: 39

Group type: COMPARATOR
Intervention: Intramuscular insulin (im)
Number of subjects: 39

Group type: COMPARATOR
Intervention: Subcutaneous insulin (sc)
Number of subjects: 39

Group type: COMPARATOR
Intervention: Lean patients
Number of subjects: 39

Group type: COMPARATOR
Intervention: Obese patients
Number of subjects: 39
Study: 31607720

Group type: EXPERIMENTAL
Intervention: Honey applied to the wound after tooth extraction
Number of subjects: 51

Group type: COMPARATOR
Intervention: Normal saline solution (NSS) applied to the wound after tooth extraction
Number of subjects: 51
Study: 28693596

Group type: EXPERIMENTAL
Intervention: Facilitation intervention (standard CPG implementation plus facilitation)
Number of subjects: 4

Group type: COMPARATOR
Intervention: Standard implementation of clinical practice guidelines (CPGs)
Number of subjects: 4
Study: 25909619

Group type: EXPERIMENTAL
Intervention: Sevoflurane with laryngeal mask
Number of subjects: 65
Study: 23702058

Group type: EXPERIMENTAL
Intervention: Supination-Flexion (SF) technique
Number of subjects: 150

Group type: EXPERIMENTAL
Intervention: Hyperpronation (HP) technique
Number of subjects: 150

Group type: COMPARATOR
Intervention: Both techniques
Number of subjects: 150
Study: 21357180

Group type: EXPERIMENTAL
Intervention: Co-meditation (shared or cross-breathing)
Number of subjects: 26
Study: 19641488

Group type: EXPERIMENTAL
Intervention: Escitalopram or Nortriptyline
Number of subjects: 796

Group type: EXPERIMENTAL
Intervention: Nortriptyline
Number of subjects: 796
Study: 18694136

Group type: EXPERIMENTAL
Intervention: Non-interruptive alert within electronic medical record prompting lab orders with new prescriptions
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group (no non-interruptive alert)
Number of subjects: 0
Study: 16821203

Group type: EXPERIMENTAL
Intervention: Surgical treatment (transsphenoidal surgery)
Number of subjects: 28

Group type: EXPERIMENTAL
Intervention: Pharmacological treatment (Sandostatin LAR, 20 mg im, monthly)
Number of subjects: 28

Group type: COMPARATOR
Intervention: Healthy control group
Number of subjects: 28
Study: 11843524

Group type: EXPERIMENTAL
Intervention: Mechanical valves (aortic)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Tissue valves (aortic)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Mechanical mitral valves
Number of subjects: 0

Group type: COMPARATOR
Intervention: Mitral tissue valves
Number of subjects: 0

Group type: COMPARATOR
Intervention: Tissue valves (general)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Mechanical valves (general)
Number of subjects: 0
Study: 10350382

Group type: EXPERIMENTAL
Intervention: Continuous infusion (CI) of meropenem: 2 g iv loading dose followed by 3 g continuous infusion over 24 h
Number of subjects: 15

Group type: COMPARATOR
Intervention: Intermittent administration (IA) of meropenem: 2 g iv every 8 h
Number of subjects: 15
Study: 8596317

Group type: EXPERIMENTAL
Intervention: Subcutaneous dalteparin (Fragmin; 120 IU per kg bodyweight [maximum 10 000 IU] twice daily for 6 days then 7500 IU once daily for the next 35-45 days)
Number of subjects: 1506

Group type: EXPERIMENTAL
Intervention: Subcutaneous dalteparin (Fragmin)
Number of subjects: 1506
Study: 1959860

Group type: EXPERIMENTAL
Intervention: Insulin and glucagon therapy (30 U insulin and 3 mg glucagon in 250 ml 5% dextrose over 12 hr each day for 3 wk)
Number of subjects: 86

Group type: COMPARATOR
Intervention: Placebo (identical regime to insulin and glucagon)
Number of subjects: 86

Group type: EXPERIMENTAL
Intervention: Insulin and glucagon therapy
Number of subjects: 86

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 86
Study: 7337944

Group type: EXPERIMENTAL
Intervention: Dexamethasone phosphate (DMP)
Number of subjects: 172

Group type: EXPERIMENTAL
Intervention: Methylprednisolone succinate (MPS)
Number of subjects: 172

Group type: COMPARATOR
Intervention: Saline (Control)
Number of subjects: 172

Group type: EXPERIMENTAL
Intervention: Steroid-treated group (DMP + MPS)
Number of subjects: 172
Study: 31755948

Group type: EXPERIMENTAL
Intervention: Rifampin therapy for at least 14 days within 90 days of diagnosis
Number of subjects: 6174

Group type: COMPARATOR
Intervention: No rifampin therapy
Number of subjects: 6174
Study: 28774794

Group type: EXPERIMENTAL
Intervention: Moderate-intensity aerobic exercise for 20 minutes
Number of subjects: 9
Study: 26477692

Group type: EXPERIMENTAL
Intervention: ETABJ (matched etanercept and 50 ml blueberry juice daily)
Number of subjects: 201

Group type: COMPARATOR
Intervention: ETAPJ (matched etanercept and placebo juice)
Number of subjects: 201

Group type: COMPARATOR
Intervention: ETA (50 mg of etanercept twice weekly)
Number of subjects: 201
Study: 23566183

Group type: EXPERIMENTAL
Intervention: Exercise intervention (details not specified)
Number of subjects: 22

Group type: COMPARATOR
Intervention: Control group (details not specified)
Number of subjects: 22
Study: 21698987

Group type: EXPERIMENTAL
Intervention: DenShield desensitizing system (in-office application of DenShield Starter paste and at-home use of DenShield dentifrices for 6 months)
Number of subjects: 31

Group type: COMPARATOR
Intervention: Placebo (distilled water)
Number of subjects: 31
Study: 19705205

Group type: COMPARATOR
Intervention: Black patients
Number of subjects: 716
Study: 17189962

Group type: EXPERIMENTAL
Intervention: Nicotine patch plus venlafaxine
Number of subjects: 116

Group type: COMPARATOR
Intervention: Nicotine patch plus placebo
Number of subjects: 116
Study: 15371578

Group type: EXPERIMENTAL
Intervention: Peginterferon alfa-2a monotherapy (180 microg once weekly)
Number of subjects: 537

Group type: EXPERIMENTAL
Intervention: Peginterferon alfa-2a plus lamivudine (100 mg daily)
Number of subjects: 537

Group type: COMPARATOR
Intervention: Lamivudine monotherapy (100 mg daily)
Number of subjects: 537
Study: 11773925

Group type: EXPERIMENTAL
Intervention: Angina clinic (optimized antianginal medications)
Number of subjects: 535

Group type: COMPARATOR
Intervention: Usual care (no intervention)
Number of subjects: 535
Study: 9842823

Group type: EXPERIMENTAL
Intervention: Oral clonidine 5 microg/kg 90 min before spinal anesthesia
Number of subjects: 48

Group type: COMPARATOR
Intervention: Control group (no clonidine)
Number of subjects: 48
Study: 8080740

Group type: EXPERIMENTAL
Intervention: Intact A5B7 IgG1 mouse monoclonal antibody (MAb) to CEA
Number of subjects: 19

Group type: EXPERIMENTAL
Intervention: F(ab')2 fragment of the same antibody
Number of subjects: 19

Group type: COMPARATOR
Intervention: Control group not explicitly mentioned
Number of subjects: 19
Study: 2757960

Group type: EXPERIMENTAL
Intervention: Treatment response
Number of subjects: 660

Group type: EXPERIMENTAL
Intervention: Stage C treatment
Number of subjects: 660

Group type: EXPERIMENTAL
Intervention: Age and response to treatment
Number of subjects: 660

Group type: EXPERIMENTAL
Intervention: Gender differences
Number of subjects: 660

Group type: EXPERIMENTAL
Intervention: Causes of death analysis
Number of subjects: 660
Study: 862429

Group type: EXPERIMENTAL
Intervention: Synemol cream (0.025%)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Diproson cream (0.05%)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Aristocort‐A cream (0.5%)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Valisone cream (0.1%)
Number of subjects: 0
Study: 31675420

Group type: EXPERIMENTAL
Intervention: Combined Contraceptive Vaginal Rings (CCVR)
Number of subjects: 130

Group type: EXPERIMENTAL
Intervention: Switching from COCP to CCVR
Number of subjects: 130

Group type: COMPARATOR
Intervention: Crossover from CCVR to COCPs or NET-EN
Number of subjects: 130

Group type: COMPARATOR
Intervention: Norethisterone Oenanthate (NET-EN)
Number of subjects: 130

Group type: COMPARATOR
Intervention: Combined Oral Contraceptive Pills (COCPs)
Number of subjects: 130
Study: 30992659

Group type: EXPERIMENTAL
Intervention: KM-819 (FAS-associated factor 1 inhibitor)
Number of subjects: 0
Study: 27755057

Group type: EXPERIMENTAL
Intervention: Programmed Intermittent Epidural Bolus (PIEB) of 10 mL of bupivacaine 0.0625% with fentanyl 2 μg/mL
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: PIEB with varying intervals (30, 40, 50, 60 minutes)
Number of subjects: 40
Study: 26102447

Group type: EXPERIMENTAL
Intervention: HITIDES intervention (collaborative care for depression)
Number of subjects: 249

Group type: COMPARATOR
Intervention: Usual care (enhanced usual care)
Number of subjects: 249
Study: 23800977

Group type: EXPERIMENTAL
Intervention: perindopril 10 mg/day
Number of subjects: 120

Group type: EXPERIMENTAL
Intervention: enalapril 20 mg/day
Number of subjects: 120

Group type: EXPERIMENTAL
Intervention: losartan 100 mg/day
Number of subjects: 120

Group type: EXPERIMENTAL
Intervention: telmisartan 80 mg/day
Number of subjects: 120
Study: 21711255

Group type: EXPERIMENTAL
Intervention: Preventive treatment from day 1 without detoxification
Number of subjects: 61

Group type: COMPARATOR
Intervention: Standard outpatient detoxification program without preventive treatment from day 1
Number of subjects: 61

Group type: COMPARATOR
Intervention: No specific treatment
Number of subjects: 61

Group type: EXPERIMENTAL
Intervention: Preventive treatment
Number of subjects: 61
Study: 18353314

Group type: EXPERIMENTAL
Intervention: 1 mg reteplase in 300 mL Ringer's lactate
Number of subjects: 26

Group type: COMPARATOR
Intervention: 300 mL Ringer's lactate only
Number of subjects: 26

Group type: EXPERIMENTAL
Intervention: Not applicable
Number of subjects: 26
Study: 16442897

Group type: EXPERIMENTAL
Intervention: Glucose-insulin-potassium (GIK) infusion during primary PCI
Number of subjects: 81

Group type: COMPARATOR
Intervention: Non-GIK group (control)
Number of subjects: 81

Group type: EXPERIMENTAL
Intervention: Comparison of GIK vs Non-GIK
Number of subjects: 81
Study: 15803238

Group type: EXPERIMENTAL
Intervention: Low-pressure pneumoperitoneum combined with intraperitoneal saline washout (LPSW)
Number of subjects: 124

Group type: COMPARATOR
Intervention: Low-pressure pneumoperitoneum (LP)
Number of subjects: 124
Study: 11331141

Group type: EXPERIMENTAL
Intervention: Fluvoxamine
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: Imipramine
Number of subjects: 24

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 24
Study: 9204744

Group type: EXPERIMENTAL
Intervention: Minicholecystectomy (MC)
Number of subjects: 60

Group type: COMPARATOR
Intervention: Conventional cholecystectomy (CC)
Number of subjects: 60
Study: 8490078

Group type: EXPERIMENTAL
Intervention: Lansoprazole 30 mg daily for 4 weeks
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo, H2-antagonists, or omeprazole
Number of subjects: 0
Study: 3130687

Group type: EXPERIMENTAL
Intervention: Oxamniquine treatment
Number of subjects: 40

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 40
Study: 29344879

Group type: EXPERIMENTAL
Intervention: Aspirin 100 mg/day
Number of subjects: 184

Group type: COMPARATOR
Intervention: Placebo 100 mg/day
Number of subjects: 184
Study: 27956407

Group type: EXPERIMENTAL
Intervention: Atorvastatin treatment for 12 weeks
Number of subjects: 55

Group type: COMPARATOR
Intervention: LMCA segments with HRM
Number of subjects: 55
Study: 24277055

Group type: EXPERIMENTAL
Intervention: remote ischemic preconditioning (IPC)
Number of subjects: 19

Group type: COMPARATOR
Intervention: sham intermittent forearm ischemia (control)
Number of subjects: 19
Study: 23880151

Group type: EXPERIMENTAL
Intervention: Self-vaginal sampling
Number of subjects: 2000

Group type: COMPARATOR
Intervention: Health professional-guided cervical sampling
Number of subjects: 2000

Group type: EXPERIMENTAL
Intervention: Cervical cytology classified as normal
Number of subjects: 2000

Group type: EXPERIMENTAL
Intervention: Cytological samples classified as ASC-US+
Number of subjects: 2000

Group type: EXPERIMENTAL
Intervention: Cytological samples classified as LSIL
Number of subjects: 2000

Group type: EXPERIMENTAL
Intervention: Cytological samples classified as HSIL
Number of subjects: 2000
Study: 19590947

Group type: EXPERIMENTAL
Intervention: Brief and intensive behavioral interventions
Number of subjects: 1483
Study: 17258218

Group type: EXPERIMENTAL
Intervention: Motivational interviewing
Number of subjects: 60

Group type: COMPARATOR
Intervention: Standard care
Number of subjects: 60

Group type: COMPARATOR
Intervention: Both treatment groups
Number of subjects: 60
Study: 17043834

Group type: EXPERIMENTAL
Intervention: 10% urea lacquer applied once daily for 28 days
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: 10% urea lacquer applied twice daily for 28 days
Number of subjects: 60

Group type: COMPARATOR
Intervention: Untreated control (other hand)
Number of subjects: 60
Study: 12393429

Group type: EXPERIMENTAL
Intervention: Concurrent treatment with fludarabine and rituximab
Number of subjects: 104

Group type: COMPARATOR
Intervention: Sequential treatment with fludarabine followed by rituximab
Number of subjects: 104
Study: 12160584

Group type: EXPERIMENTAL
Intervention: Castration plus Anandron
Number of subjects: 399

Group type: COMPARATOR
Intervention: Surgical castration
Number of subjects: 399
Study: 10513457

Group type: EXPERIMENTAL
Intervention: Fananserin (600 mg/day) with slow titration (100 mg increases every 3 days)
Number of subjects: 26

Group type: EXPERIMENTAL
Intervention: Fananserin (600 mg/day) with rapid titration (200 mg increases every 3 days)
Number of subjects: 26

Group type: EXPERIMENTAL
Intervention: Fananserin (600 mg/day) with intermediate titration (100 mg increases every 2 days)
Number of subjects: 26

Group type: EXPERIMENTAL
Intervention: Fananserin (multiple doses)
Number of subjects: 26
Study: 8055896

Group type: EXPERIMENTAL
Intervention: Isokinetic training at 4.19 rad.s‐1 (n = 13)
Number of subjects: 23

Group type: EXPERIMENTAL
Intervention: Isokinetic training at 1.05 rad.s‐1 (n = 10)
Number of subjects: 23

Group type: COMPARATOR
Intervention: Control group (n = 10) performing no training
Number of subjects: 23
Study: 2898027

Group type: COMPARATOR
Intervention: Cholestyramine resin (12 g, twice a day)
Number of subjects: 264

Group type: EXPERIMENTAL
Intervention: Lovastatin (20 mg, twice a day)
Number of subjects: 264

Group type: EXPERIMENTAL
Intervention: Lovastatin (40 mg, twice a day)
Number of subjects: 264
Study: 30060902

Group type: COMPARATOR
Intervention: Standard triple therapy (CLA): clarithromycin 500mg, lansoprazole 30mg, amoxicillin 1g, all bid for 10 days
Number of subjects: 227

Group type: EXPERIMENTAL
Intervention: Levofloxacin-based therapy (PLA): pantoprazole 80mg, levofloxacin 500mg, azithromycin 500mg, all od for 10 days
Number of subjects: 227
Study: 28588166

Group type: EXPERIMENTAL
Intervention: Local steroid injection (triamcinolone acetate)
Number of subjects: 80

Group type: COMPARATOR
Intervention: Therapeutic ultrasound
Number of subjects: 80
Study: 25577713

Group type: EXPERIMENTAL
Intervention: Bupivacaine (0.3 mL per side, intranasally)
Number of subjects: 87

Group type: COMPARATOR
Intervention: Normal saline solution (0.3 mL per side, intranasally)
Number of subjects: 87